Journal of Hematology & Thromboembolic Diseases : Citations & Metrics Report
Articles published in Journal of Hematology & Thromboembolic Diseases have been cited by esteemed scholars and scientists all around the world. Journal of Hematology & Thromboembolic Diseases has got h-index 16, which means every article in Journal of Hematology & Thromboembolic Diseases has got 16 average citations.
Following are the list of articles that have cited the articles published in Journal of Hematology & Thromboembolic Diseases.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Year wise published articles |
62 | 50 | 23 | 6 | 15 |
Year wise citations received |
136 | 146 | 135 | 123 | 106 |
Journal total citations count | 1065 |
Journal impact factor | 2.67 |
Journal 5 years impact factor | 4.32 |
Journal cite score | 4.94 |
Journal h-index | 16 |
Journal h-index since 2019 | 12 |
Important citations (901)
jose b, jose jv, paul m (2018) dapsone-induced methemoglobinemia: blue cures blue. j pharmacol pharmacother. 9:117. |
|
iida t, hirayama d, sudo g, mitsuhashi k, igarashi h, yamashita k et al.(2019) chronic intestinal pseudo-obstruction due to al amyloidosis: a case report and literature review. j clin gastroenterol. 12:176-81. |
|
gadisseur ws, de raeve h, jacques jm, yonggoo k, myungshin k, francisca v et al. (2019) bone marrow histology in calr mutated thrombocythemia and myelofi brosis: results from two cross sectional studies in 70 newly diagnosed jak2/mpl wild type thrombocythemia patients. international journal of bone marrow research. |
|
de raeve h, fostier k, valster f, potters v, kim y, kim m et al. (2018) bone marrow histology is a pathognomonic clue to each of the jak2 v617f, mpl, 515 and calreticulin mutated thrombocythemia in myeloproliferative neoplasms. clinical research in hematology. 2:1-7. |
|
momot ap, nikolaeva mg, yasafova nn, zainulina ms, momot ka, taranenko ia (2019) clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age. journal of blood medicine. 10:255. |
|
obstetrics g (2019) clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age. journal of blood medicine. 4:54-11. |
|
wautier jl, wautier mp (2018) molecular links between erythrocyte adhesion and vascular dysfunction in diabetes mellitus, polycythemia vera, retinal vascular occlusion. j hematol thrombo dis. 6:2. |
|
ayemoba o, hussain n, umar t, ajemba-life a, kene t, edom u et al. (2019) establishment of reference values for selected haematological parameters in young adult nigerians. plos one.14:e0213925 |
|
onwurah o, onyenekwe c, ifeanyichukwu m, ezeugwunne i, odiegwu c, igweze z (2018) haematological values for children, adults and geriatrics in nnewi and environs, anambra state, nigeria. j hematol thrombo dis. 6:23-6. |
|
ayemoba o, hussain n, umar t, ajemba-life a, kene t, edom u et al. (2019) establishment of reference values for selected haematological parameters in young adult nigerians. plos one.14:e0213925 |
|
Dijk m, holkers j, voskamp p, giannetti bm, et al. (2016) how dextran sulfate affects c1-inhibitor activity: a model for polysaccharide potentiation. structure 24: 2182-2189. |
|
Tradtrantip l, asavapanumas n, phuan pw, verkman as (2014) potential therapeutic benefit of c1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model. plos one 9: e106824. |
|
Hansen hg, nilsson cn, lund am, kol s, grav lm et al. (2014) versatile microscale screening platform for improving recombinant protein productivity in chinese hamster ovary cells. scientific reports. 5: 18016-18019. |
|
Dijk m, holkers j, voskamp p, giannetti bm, et al. (2016) how dextran sulfate affects c1-inhibitor activity: a model for polysaccharide potentiation. structure 24: 2182-2189. |
|
risitano am (2017) future strategies of complement inhibition in paroxysmal nocturnal hemoglobinuria. inparoxysmal nocturnal hemoglobinuria 2017.pp:319-346) japan. |
|
Risitano am (2015) complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going. expert opinion on orphan drugs 3: 691-704. |
|
Alashkar f, dührsen u, röth a (2016) horse antiâ€thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or noâ€go?. european journal of haematology 97: 403-405. |
|
Risitano am, marotta s (2016) therapeutic complement inhibition in complement-mediated hemolytic anemias: past, present and future. inseminars in immunology 28: 223-240. |
|
risitano am (2015) current and future pharmacologic complement inhibitors. hematology/oncology clinics of north america 29: 561-582. |
|
blas dobón ja, martínez e, andujar cejalvo mj, jl martínez gimeno, aguar p carrascosa (2015) perioperatorio handling of anticoagulants and antiplatelet fármacos in the patient with hip fracture. |
|